2023年美国临床肿瘤学会年会(ASCO)将于2023年6月2日至6日在美国芝加哥举行,全球肿瘤学界最大的年度大会汇集了来自世界各地的肿瘤学专业人士,一年一度的ASCO年会汇聚了全球临床肿瘤学研究的精英,被公认为全球最重要的肿瘤学术会议。教育课程以世界知名的教师为特色,讨论最先进的治疗方式、新疗法和该领域正在进行的争议...
At this year’s ASCO Annual Conference, we saw big wins for new medicines in lung and breast cancer. And while there were many insights from our time in Chicago, four themes stood out. Here's what ourReal World EvidenceandClinical Researchteams identified as their top four takeaways: 1. ...
ASCO 20236/2/2023 - 6/6/2023Chicago IL, United States ASCO 20226/3/2022 - 6/7/2022Chicago IL, United States ASCO 20186/1/2018 - 6/5/2018Chicago IL, United States Related Events: Annual Conference on Shock 2025 5/31/2025 - 6/3/2025 ...
2025 ASCO Annual Meeting May 30 - Jun 04, 2025 Online & In-Person | Chicago, IL Register Most Viewed text_snippet Videos & Slides 2023 ASCO Annual Meeting Phase II trial of neoadjuvant osimertinib for surgically resectableEGFR-mutated non-small cell lung cancer. ...
Hello. I am Mark Lewis, director of gastrointestinal oncology at Intermountain Health in Utah. I am speaking at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, where we have seen some interesting new data in gastrointestinal (GI) cancers that I'd like to tell...
442#Background:In-person conference attendance contributes significantly to a professional's annual greenhouse gas (GHG) emissions. However, estimating conference emissions has often relied on assumptions about attendee numbers and travel, especially for investigations of medical conferences. This project ...
$亘喜生物(GRCL)$,在asco2023上,$传奇生物(LEGN)$的CARTITUBE-1的长期数据,大家可以与亘喜的012F 对比一下。期待得到专业人员的深入分析指教。 Sign insearch CARTITUDE-1 final results: Phase 1b/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed/refractory multiple myeloma...
In 1996, the National Comprehensive Cancer Network®published its first set of Clinical Practice Guidelines in Oncology (NCCN Guidelines®) covering eight tumor types. Guidelines are now published for more than 60 tumor types, subtypes, and topics. During the NCCN’s 28th Annual Conference, upda...
AstraZeneca targets $80 billion in revenue by 2030, layoffs at Bayer, BMS and Pfizer continue to generate attention across the biopharma industry, Takeda takes a deep dive into the molecular glue space and conference season is in full swing.
Professor Park Yeon-hee of the Department of Hematology/Oncology at Samsung Medical Center presented the overall survival (OS) analysis from the Young-PEARL study orally at the world's largest cancer conference, held from May 31 to June 4 in Chicago, Ill. ...